Premium
Response to platelet‐activating factor of platelets from patients with multiple sclerosis
Author(s) -
Khan S. N.,
Belin J.,
Smith A. D.,
Sidey M.,
Zilkha K. J.
Publication year - 1985
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1985.tb03191.x
Subject(s) - platelet , chemistry , verapamil , medicine , platelet activating factor , platelet aggregation , antagonist , phospholipase a2 , multiple sclerosis , endocrinology , biochemistry , calcium , immunology , enzyme , receptor
– The response of Multiple Sclerosis (MS) and control platelets to different concentrations of platelet‐activating factor was studied. At concentrations in the range 10 −7 to 10 −5 M, it was found that the MS platelets tended to aggregate fully at lower concentrations than was the case with control platelets. At a concentration of 10 −6 M, it was found that in 19 cases the MS platelets gave a full aggregation response whilst 4 cases showed biphasic but full aggregation, whereas at this concentration the control platelets showed full aggregation in only 2 cases, biphasic but less complete aggregation in 5 cases and reversible aggregation in 16 cases. In crossover studies, it could be shown that MS platelets resuspended in control platelet‐poor plasma still showed enhanced aggregability and that the response of control platelets was unaffected by resuspension in MS platelet‐poor plasma. Differences were also seen in susceptibility of platelets of MS and control subjects to inhibition by indomethacin, bromo‐phenacyl bromide (a phospholipase inhibitor) and verapamil (a Ca 2 + antagonist). It is suggested that the hyperaggregability of the MS platelets could reside in the platelets themselves, and may be associated with enhanced phospholipase activity.